Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECRESCENDO phase 2 de-escalation study in early HER2-positive, estrogen receptor-negative, node-negative breast cancer
MOH_2022-10-19_012130Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of trastuzumab, sponsored by Institut Jules Bordet. Started Oct 2022; status: completed.
02
Drugs
Beyond the preview
Go deeper on MOH_2022-10-19_012130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-19_012130.